Repligen Corporation $RGEN Position Increased by Osterweis Capital Management Inc.

Key Points

• Osterweis Capital Management Inc. increased its stake in Repligen Corporation by 18.0% this quarter, purchasing an additional 11,080 shares, bringing its total ownership to approximately 72,765 shares valued at $9.26 million.
• Repligen Corporation's stock received mixed ratings from analysts, with Wall Street Zen downgrading it to a "hold" while Wolfe Research upgraded it to "outperform" with a price target of $160.00.
• In the most recent quarter, Repligen reported revenues of $182.37 million, exceeding expectations, but earnings per share fell short of the consensus estimate, recording $0.37 compared to an expected $0.40.

Osterweis Capital Management Inc. grew its holdings in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 18.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 72,765 shares of the biotechnology company's stock after purchasing an additional 11,080 shares during the period. Osterweis Capital Management Inc. owned approximately 0.13% of Repligen worth $9,259,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD lifted its stake in Repligen by 11.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock valued at $1,027,165,000 after buying an additional 743,815 shares in the last quarter. Point72 Asset Management L.P. lifted its stake in Repligen by 183.1% in the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock valued at $132,227,000 after buying an additional 594,189 shares in the last quarter. Alyeska Investment Group L.P. purchased a new stake in Repligen in the 4th quarter valued at approximately $53,428,000. Nuveen LLC purchased a new stake in Repligen in the 1st quarter valued at approximately $35,536,000. Finally, Artemis Investment Management LLP lifted its stake in Repligen by 110.1% in the 1st quarter. Artemis Investment Management LLP now owns 323,229 shares of the biotechnology company's stock valued at $41,128,000 after buying an additional 169,397 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on RGEN shares. Wall Street Zen lowered Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Royal Bank Of Canada increased their price target on Repligen from $193.00 to $204.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 30th. Barclays assumed coverage on Repligen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $150.00 price target on the stock. Evercore ISI cut their price target on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a research note on Tuesday, July 8th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Repligen presently has a consensus rating of "Moderate Buy" and a consensus target price of $169.45.

Repligen Stock Up 4.3%

Shares of Repligen stock traded up $5.14 during trading hours on Friday, hitting $124.79. 775,437 shares of the company's stock traded hands, compared to its average volume of 898,905. The stock has a 50 day simple moving average of $121.66 and a 200-day simple moving average of $131.54. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. The company has a market cap of $7.02 billion, a PE ratio of -499.14, a PEG ratio of 2.20 and a beta of 1.05. Repligen Corporation has a twelve month low of $102.96 and a twelve month high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The company had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. During the same period in the previous year, the business posted $0.40 EPS. The business's revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Equities research analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Insider Activity at Repligen

In related news, Director Martin D. Madaus purchased 1,800 shares of Repligen stock in a transaction dated Friday, August 8th. The shares were acquired at an average price of $112.13 per share, with a total value of $201,834.00. Following the completion of the transaction, the director owned 1,800 shares of the company's stock, valued at approximately $201,834. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.20% of the company's stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.